The review, led by Maged T. Ghoche and Kalil G. Abdullah of Northwell Health, together with colleagues at the University of Pittsburgh and the University of Texas Southwestern Medical Center, systematically searched PubMed and Embase from inception through August 19, 2026. The team included in vivo preclinical experiments and clinical studies evaluating ketogenic diets or methionine restriction in glioma, extracting data on interventions, comparators, concurrent oncologic treatments, metabolic effects, safety, feasibility, and outcomes. Because most clinical studies were early-phase, single-arm feasibility investigations, the researchers allowed clinical studies with or without a non-diet comparator, then assessed risk of bias with design-appropriate tools and synthesized effects narratively and by direction of effect.

The search yielded 43 eligible reports: 14 preclinical and 18 clinical reports of ketogenic diet interventions, and 9 preclinical and only 2 clinical studies of methionine restriction. That imbalance itself tells a story. Ketogenic diets, which drastically cut carbohydrates and elevate fat intake to push the body into ketosis, have generated nearly two decades of clinical curiosity in neuro-oncology. Methionine restriction, by contrast, remains largely confined to the laboratory, despite a compelling mechanistic rationale rooted in the peculiar metabolic addictions of glioma cells.

The scientific logic behind both diets traces back to a century-old observation. In the 1920s, Otto Warburg described how cancer cells consume glucose voraciously even in the presence of oxygen, a phenomenon now known as the Warburg effect. Glioblastoma is a quintessential glycolytic tumor, and the healthy brain, uniquely dependent on glucose, can partially switch to ketone bodies when glucose is scarce. The therapeutic hypothesis is elegant: if ketone bodies can fuel normal neurons but not tumor cells that have lost key ketogenic enzymes, a ketogenic diet might create a metabolic mismatch that harms the tumor while sparing the brain. Studies cited in the review, including work by Tisdale and colleagues in the 1980s and Maurer and colleagues in 2011, documented loss of acetoacetate coenzyme A transferase activity and differential ketone body utilization in glioma cell lines compared with neurons, providing a cellular foundation for the strategy.

Preclinical results, however, proved strikingly heterogeneous. Several diet-only experiments in mice reduced tumor growth or prolonged survival, including Seyfried’s calorically restricted ketogenic diet work from 2007 and Abdelwahab’s 2012 demonstration that a ketogenic diet acted as an effective adjuvant to radiation therapy in malignant glioma. Other studies showed limited activity, and one informative trial by de Feyter and colleagues in 2016 found that a ketogenic diet increased ketone body transport and oxidation in RG2 and 9L gliomas without actually affecting tumor growth, a reminder that fuel delivery does not equal fuel dependence. The most dramatic preclinical effects emerged when diets were combined with other modalities: radiation, antiangiogenic therapy, glutamine targeting, or immune modulation. Mukherjee and colleagues in 2019 reported therapeutic benefit from combining a calorie-restricted ketogenic diet with glutamine targeting in late-stage experimental glioblastoma, and more recent work has shown that ketogenic diets can reshape the tumor immune microenvironment and even induce an inflammatory reactive astrocyte phenotype that slows glioma growth.

Methionine restriction operates through a different axis entirely. Many tumor cells, including glioma cells, display methionine dependence, an inability to proliferate when the essential amino acid methionine is scarce. Because methionine feeds one-carbon metabolism, polyamine synthesis, and epigenetic regulation through S-adenosylmethionine, withdrawing it can cripple tumor growth and sensitize cells to chemotherapy. The review highlights work showing that methionine restriction does not induce MGMT, the resistance enzyme that blunts temozolomide, and thereby greatly improves chemotherapy efficacy in orthotopic mouse models. Other studies have shown that restricting methionine and cysteine together sensitizes gliomas to ferroptosis, an iron-dependent form of cell death, and that methionine deprivation can alter the epigenome in H3K27M-mutant glioma. Yet the clinical translation has barely begun: only two small clinical trials, both combining methionine-free diets with chemotherapy, are included in the entire evidence base.

On the clinical side, the review’s findings are candid. Studies such as the ERGO pilot trial of a ketogenic diet in recurrent glioblastoma, the KEATING randomized feasibility study, the ERGO2 trial of calorie-restricted ketogenic diets and fasting alongside reirradiation, and a series of phase I safety trials in newly diagnosed patients consistently demonstrated that ketogenic diets are feasible and can induce ketosis, lower glucose, and produce measurable metabolic changes. Some reports described striking individual long-term survivors, but the review notes that such anecdotes emerged from small, uncontrolled, single-arm studies in which patients also received surgery, radiotherapy, chemotherapy, bevacizumab, corticosteroids, and other co-interventions. In nearly every case, the effects of the diet cannot be reliably separated from the effects of concurrent treatment. The authors conclude that clinical evidence primarily supports feasibility and metabolic activity, not independent efficacy.

The confounding problem is not trivial. Corticosteroids, routinely given to glioblastoma patients to control brain swelling, raise blood glucose and can directly counteract the metabolic goals of a ketogenic diet. Bevacizumab alters tumor vascularity. Tumor molecular subtype, particularly IDH mutation status, reshapes tumor metabolism in ways that may determine whether a glycolytic strategy can work at all. Without standardized reporting of the glucose-ketone index, careful documentation of treatment and steroid use, and longitudinal nutritional assessment, comparisons across studies become nearly impossible. The review calls explicitly for randomized trials with intention-to-treat analysis as the necessary next step before these diets can be recommended as effective glioma therapy.

For patients and families who have embraced ketogenic diets, sometimes with missionary zeal, the message is nuanced. The diets are not dangerous in most studied contexts, they genuinely change systemic and possibly intratumoral metabolism, and the biology underlying them is real. But biology is not yet medicine. The gap between a mouse whose glioma shrinks under a calorie-restricted ketogenic diet combined with glutamine targeting and a human patient whose survival depends on whether the diet independently matters remains wide. What this systematic review offers is a map of that gap: forty-three studies, a clear mechanistic rationale, consistent proof that the diets can be delivered safely, and an honest admission that no one has yet proven they work on their own. The next generation of rigorously controlled randomized trials will determine whether dietary metabolic therapy earns a place alongside surgery, radiation, and chemotherapy, or whether it remains one of oncology’s most seductive unfinished ideas.

Subject of Research: Metabolic modulation of glioblastoma through ketogenic diet and methionine restriction

Article Title: Metabolic modulation of glioblastoma by dietary intervention: a systematic review

Article References: Ghoche, M. T., Miki, K., Yuan, F., Mantica, M., Agnihotri, S., McBrayer, S. K., & Abdullah, K. G. (2026). Metabolic modulation of glioblastoma by dietary intervention: a systematic review. Journal of Neuro-Oncology, 179(3), Article 90. https://doi.org/10.1007/s11060-026-05779-x

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05779-x

Keywords: glioblastoma, ketogenic diet, methionine restriction, cancer metabolism, dietary intervention, metabolic therapy, systematic review, clinical trials, brain cancer, Warburg effect, glucose-ketone index, glioma